Fact versus fiction: bridging contrasting medicinal cannabis information needs.
cancer
carers
information resource
medicinal cannabis
palliative care
patients
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
11
11
2020
received:
04
09
2020
accepted:
19
11
2020
entrez:
22
6
2021
pubmed:
23
6
2021
medline:
10
8
2021
Statut:
ppublish
Résumé
Regulatory changes now permit the availability and prescribing of medicinal cannabis in Australia. Public awareness and patient interest are high. Using a co-design approach involving cancer patients, carers and oncology and palliative care clinicians, two information resources were developed to provide readily available sources of important information for cancer patients and clinicians who are considering the use of medicinal cannabis. Focus groups and evaluation interviews revealed some areas of dissonance between consumers and clinicians concerning aspects of medicinal cannabis.
Substances chimiques
Medical Marijuana
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
975-979Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Therapeutic Goods Administration (TGA). Guidance for the Use of Medicinal Cannabis in Australia: Overview. Canberra: Department of Health, Commonwealth of Australia; 2017.
Pergam SA, Woodfield MC, Lee CM, Cheng GS, Baker KK, Marquis SR et al. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer 2017; 123: 4488-97.
Benze G, Geyer A, Alt-Epping B, Nauck F. Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients: a systematic review. Schmerz 2012; 26: 481-99.
Santana TA, Trufelli DC, de Matos LL, Cruz FM, Del Giglio A. Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting. Support Care Cancer 2015; 23: 213-22.
Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015; 313: 2456-73.
National Institute for Health and Care Excellence (NICE). Cannabis-Based Medicinal Products (NG144). 2019 [cited 2020 Jul 1]. Available from URL: https://www.nice.org.uk/guidance/ng144/resources/cannabisbased-medicinal-products-pdf-66141779817157
Allan GM, Finley CR, Ton J, Perry D, Ramji J, Crawford K et al. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician 2018; 64: e78-94.
Australian New Zealand Clinical Trials Registry (ANZCTR). Sydney; 2018 [cited 2020 Jul 1]. Available from URL: http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=cANNABIS&isBasic=True
Mersiades AJ, Tognela A, Haber PS, Stockler M, Lintzeris N, Simes J et al. Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). BMJ Open 2018; 8: 1-8.
Mücke M, Weier M, Carter C, Copeland J, Degenhardt L, Cuhls H et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle 2018; 9: 220-34.
Luckett T, Phillips J, Lintzeris N, Allsop D, Lee J, Solowij N et al. Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation. Intern Med J 2016; 46: 1269-75.
Good P, Haywood A, Gogna G, Martin J, Yates P, Greer R et al. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD). BMC Palliat Care 2019; 18: 110.
Therapeutic Goods Administration (TGA). Guidance for the Use of Medicinal Cannabis for the Prevention or Management of Nausea and Vomiting in Australia. Canberra, Australia: Department of Health, Commonwealth of Australia; 2017.
Therapeutic Goods Administration (TGA). Guidance for the Use of Medicinal Cannabis in the Treatment of Palliative Care Patients in Australia. Canberra: Department of Health, Commonwealth of Australia; 2017.
Borgstrom E, Barclay S. Experience-based design, co-design and experience-based co-design in palliative and end-of-life care. BMJ Support Palliat Care 2019; 9: 60-6.
Robert G, Cornwell J, Locock L, Purushotham A, Sturmey G, Gager M. Patients and staff as codesigners of healthcare services. Br Med J 2015; 350: g7714.
Creswell JW, Creswell JD. Research Design: Qualitative, Quantitative, and Mixed Methods Approaches. Los Angeles, CA: SAGE Publications; 2017.
Shi S, Brant AR, Sabolch A, Pollom E. False news of a cannabis cancer cure. Cureus 2019; 11: e3918.
Panozzo S, Le B, Collins A, Weil J, Whyte J, Barton M et al. Who is asking about medicinal cannabis in palliative care? Intern Med J 2020; 50: 243-6.